242 related articles for article (PubMed ID: 30170097)
1. Methylglyoxal at metronomic doses sensitizes breast cancer cells to doxorubicin and cisplatin causing synergistic induction of programmed cell death and inhibition of stemness.
Roy A; Sarker S; Upadhyay P; Pal A; Adhikary A; Jana K; Ray M
Biochem Pharmacol; 2018 Oct; 156():322-339. PubMed ID: 30170097
[TBL] [Abstract][Full Text] [Related]
2. Methylglyoxal in combination with 5-Fluorouracil elicits improved chemosensitivity in breast cancer through apoptosis and cell cycle inhibition.
Ghosh S; Pal A; Ray M
Biomed Pharmacother; 2019 Jun; 114():108855. PubMed ID: 31003140
[TBL] [Abstract][Full Text] [Related]
3. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
5. Induction of mitochondrial apoptotic pathway in triple negative breast carcinoma cells by methylglyoxal via generation of reactive oxygen species.
Roy A; Ahir M; Bhattacharya S; Parida PK; Adhikary A; Jana K; Ray M
Mol Carcinog; 2017 Sep; 56(9):2086-2103. PubMed ID: 28418078
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: A mechanistic insight.
Rai G; Mishra S; Suman S; Shukla Y
Phytomedicine; 2016 Mar; 23(3):233-42. PubMed ID: 26969377
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of Hep3B hepatoma cells to cisplatin and doxorubicin by corilagin.
Gambari R; Hau DK; Wong WY; Chui CH
Phytother Res; 2014 May; 28(5):781-3. PubMed ID: 23913631
[TBL] [Abstract][Full Text] [Related]
8. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
[TBL] [Abstract][Full Text] [Related]
9. Effects of Fucoidan and Chemotherapeutic Agent Combinations on Malignant and Non-malignant Breast Cell Lines.
Abudabbus A; Badmus JA; Shalaweh S; Bauer R; Hiss D
Curr Pharm Biotechnol; 2017; 18(9):748-757. PubMed ID: 29141543
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.
Ibrahim T; Liverani C; Mercatali L; Sacanna E; Zanoni M; Fabbri F; Zoli W; Amadori D
Int J Oncol; 2013 Apr; 42(4):1263-70. PubMed ID: 23403907
[TBL] [Abstract][Full Text] [Related]
11. The Indole-3-carbinol cyclic tetrameric derivative CTet synergizes with cisplatin and doxorubicin in triple-negative breast cancer cell lines.
De Santi M; Galluzzi L; Duranti A; Magnani M; Brandi G
Anticancer Res; 2013 May; 33(5):1867-72. PubMed ID: 23645732
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between aldehyde dehydrogenase-1 and chemoresistance in breast cancer: Insights into the role of vitamin D3.
Attia YM; Hammam OA; Ammar RA; Mansour MT; Elmazar MM
Life Sci; 2020 Jul; 253():117733. PubMed ID: 32360127
[TBL] [Abstract][Full Text] [Related]
13. Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
Chang YW; Singh KP
PLoS One; 2017; 12(3):e0174227. PubMed ID: 28323900
[TBL] [Abstract][Full Text] [Related]
14. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
Kozar K; Kaminski R; Legat M; Kopec M; Nowis D; Skierski JS; Koronkiewicz M; Jakóbisiak M; Golab J
Int J Oncol; 2004 May; 24(5):1149-57. PubMed ID: 15067336
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cytotoxic activity of doxorubicin through the inhibition of autophagy in triple negative breast cancer cell line.
Aydinlik S; Erkisa M; Cevatemre B; Sarimahmut M; Dere E; Ari F; Ulukaya E
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):49-57. PubMed ID: 27842219
[TBL] [Abstract][Full Text] [Related]
16. Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo.
Lei G; Xu M; Xu Z; Lu C; Tan S
Biomed Pharmacother; 2018 Feb; 98():271-279. PubMed ID: 29272788
[TBL] [Abstract][Full Text] [Related]
17. Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228.
Pluchino LA; Choudhary S; Wang HC
Cancer Lett; 2016 Oct; 381(1):124-32. PubMed ID: 27477899
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.
Li Y; Ahmed F; Ali S; Philip PA; Kucuk O; Sarkar FH
Cancer Res; 2005 Aug; 65(15):6934-42. PubMed ID: 16061678
[TBL] [Abstract][Full Text] [Related]
19. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
[TBL] [Abstract][Full Text] [Related]
20. The synergistic effect between vanillin and doxorubicin in ehrlich ascites carcinoma solid tumor and MCF-7 human breast cancer cell line.
Elsherbiny NM; Younis NN; Shaheen MA; Elseweidy MM
Pathol Res Pract; 2016 Sep; 212(9):767-77. PubMed ID: 27493101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
